To access this element change to forms mode OFF
Grant Award View - GA289125
Developing an mRNA-based gene therapy strategy for Niemann-Pick Disease...
GA ID:
GA289125
Agency:
Department of Health and Aged Care
Approval Date:
21-Oct-2022
Publish Date:
20-Mar-2023
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2025
Value (AUD):
$599,650.36
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 22/23 1.1 Health Policy Research and Analysis
Grant Program:
Medical Research Future Fund
Grant Activity:
Developing an mRNA-based gene therapy strategy for Niemann-Pick Disease Type C1: a blueprint to treat childhood dementia
Purpose:
Niemann-Pick Disease Type C1 (NP-C1), sometimes called “Childhood Alzheimer’sâ€, is a classic example of childhood dementia. Children born with this genetic condition usually do not survive past their teenage years. There is no cure and an urgent need for new effective treatments. We will develop a new mRNA-based gene therapy for NP-C1, targeting the underlying genetic cause. This will be a proof-of-concept that could then be used to also treat other genetic conditions with childhood dementia.
GO ID:
GO Title:
MRFF – PPHRI & EPCDRI – 2022 Effective Treatments and Therapies Grant Opportunity
Internal Reference ID:
2022/MRF2023205
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA